



Adicet Bio to Participate in Fireside Chat at Canaccord Genuity 46th Annual Growth Conference

July 21, 2026

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jul. 21, 2026-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference being held from August 11-13, 2026, in Boston.

Details of the event are as follows:

Date: Tuesday, August 11, 2026

Time: 10:30 a.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio's website at <https://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20260721675362/en/>

Adicet Bio, Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Penelope Belnap

Precision AQ

Penelope.belnap@precisionaq.com

Source: Adicet Bio, Inc.